Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 47,100 shares, a decrease of 64.9% from the October 15th total of 134,300 shares. Based on an average daily volume of 135,700 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.1% of the company’s stock are short sold.

Soligenix Trading Down 3.8 %

Soligenix stock traded down $0.14 during midday trading on Friday, reaching $3.54. The company’s stock had a trading volume of 16,193 shares, compared to its average volume of 840,603. The stock’s 50-day simple moving average is $3.76 and its 200-day simple moving average is $4.36. Soligenix has a 52-week low of $1.83 and a 52-week high of $32.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SNGX. Stephens Inc. AR acquired a new position in Soligenix in the 3rd quarter valued at $184,000. Armistice Capital LLC acquired a new position in Soligenix in the 2nd quarter valued at $206,000. Finally, OLD National Bancorp IN acquired a new position in Soligenix in the 2nd quarter valued at $26,000. 3.60% of the stock is currently owned by hedge funds and other institutional investors.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.